VSC’s Post

🚀 Talk about massive.... 1Bill committed capital (unless I read that wrong)! Xaira Therapeutics Launches to Revolutionize Drug Discovery and Development with AI 🧬💊 Today marks a monumental milestone as Xaira Therapeutics embarks on a mission to reshape the landscape of medicine through the transformative power of artificial intelligence. 🌐💡 Backed by over $1 billion in committed capital from leading investors ARCH Venture Partners, Foresite Capital, and a consortium of esteemed partners, Xaira is poised to redefine the drug discovery process. 💰💡 Led by a stellar team including Dr. Marc Tessier-Lavigne, former CSO of Genentech, and co-founder Dr. David Baker, a pioneer in protein design, Xaira integrates cutting-edge AI research, extensive data generation, and robust product development to accelerate therapeutic breakthroughs. 🧪🔬 With a commitment to advancing fundamental AI research and translating discoveries into life-changing treatments, Xaira represents a bold step forward in the pursuit of better healthcare for all. Wow!🌟💊 #XairaTherapeutics #AIinHealthcare #DrugDiscoveryRevolution

💡#TechTalkWednesday4 "Introducing Xaira Therapeutics: Revolutionizing Drug Discovery with AI" Today is a big day for the biotechnology and artificial intelligence industries because Xaira Therapeutics has just launched. With support from over $1 billion from well-known investors like ARCH Venture Partners, Foresite Capital, Sequoia Capital, Lux Capital, and others, Xaira is starting a groundbreaking journey to change the way we find and make medicines. What Sets Xaira Apart? End-to-End AI Integration: Xaira is not just using AI but is re-engineering the drug discovery process from the ground up. By integrating advanced machine learning, vast data generation capabilities, and robust therapeutic product development, Xaira is positioned to revolutionize our approach to medicines. Elite Foundations: Co-founded by Dr. David Baker, a renowned figure in biochemistry and protein design, Xaira is leveraging cutting-edge AI models such as RFdiffusion and RFantibody. These models were pivotal in protein and antibody design and now form the backbone of Xaira's research initiatives. A Multidisciplinary Dynamo: With a team culled from top-tier institutions and companies, Xaira combines expertise in computational biology, drug design, and clinical development under one roof. ................................................................................................................................ An optimistic thought: With AI-driven platforms like Xaira Therapeutics improving rapidly in the biotech industry, we might soon be entering a time when personalized medicine becomes usual. Imagine treatments designed just for your genetic makeup, which could make medications more effective and reduce side effects. The accuracy and speed that AI brings could quickly make healthcare more tailored to each person's specific needs. Find out more: RFdiffusion: https://lnkd.in/eiQGQw5c Xaira Therapeutics: https://lnkd.in/ej74SKqh https://lnkd.in/ebwkKPJt #XairaTherapeutics #AIDrugDiscovery #Biotechnology #MachineLearning #HealthcareInnovation #StartupLaunch

🙏 Thanks to Speedinvest & Dealroom.co for having identified ADLIN Science as one of the companies in the area of Data Infrastructure and more concrete as an enabling technology necessary for Techbio companies in drug discovery. 🔬 We have the objective to unlock health data to accelerate drug discovery & development by enabling Techbio companies the access to deep data to train and optimize their AI models. 🤝 By being positioned between health public institutions, Techbio companies and AI solution providers, ADLIN aims to accelerate and derisk AI projects for Pharma companies and Biotechs.  💡 Our Decentralized Research Environment can do precisely this by providing the tools necessary to make data better structured & interoperable to accelerate its access & analysis to generate insights. Our initial focus is Childhood Cancers due to the great unmet needs in developing first-in-child drugs, but our technology and expertise are also aimed at Adult Oncology & Rare diseases. 👍 Thanks Estelle & Daria for the great report! Link here: https://lnkd.in/ews4rrB8 Do not hesitate to connect with us if you want to know more. #theADLINway #PrecisionMedicine #ChildhoodCancers BioLabs France | Genopole | PariSanté Campus | Agoranov

🚀 Exciting News in Drug Discovery! Isomorphic Labs, the dynamic spinout of Google AI R&D division DeepMind, is making waves with groundbreaking partnerships. 🤝💊 🌐 Isomorphic has sealed strategic deals with pharmaceutical giants Eli Lilly and Company and Novartis, valued at a combined $3 billion! 🤑 This collaboration aims to leverage AI for the discovery of innovative medications to combat various diseases. 🧬💡 🚀 Eli Lilly's partnership involves an upfront payment of $45 million to Isomorphic, with potential performance-based milestones of up to $1.7 billion, excluding royalties. Novartis, on the other hand, will provide an initial payment of $37.5 million, along with additional funding for select research costs and performance-based incentives of up to $1.2 billion (excluding royalties) over time. 📈💰 🤖 Isomorphic Labs, founded in 2021 under Alphabet, utilizes DeepMind's AlphaFold 2 AI technology to predict protein structures in the human body. Despite its imperfections, the technology has shown immense promise in designing potential drugs, exemplified by a recent endeavor to treat hepatocellular carcinoma. 🧪👾 💡 Isomorphic's CEO, Demis Hassabis, expresses excitement about the partnerships, emphasizing the shared focus on advancing drug design approaches and cutting-edge science. 🌟 🌍 The collaboration aligns cutting-edge AI with medicinal chemistry, data science, and deep disease area expertise, opening new possibilities in AI-driven drug discovery. The potential for groundbreaking advancements in therapeutics is enormous! 🚀🔍 #DrugDiscovery #AIInHealthcare #BiopharmaInnovation #IsomorphicLabs #EliLilly #Novartis #AlphaFold2 #InnovativePartnerships 🧬💊🤖

🔬 Exciting News in the World of Biotech! 🌐 Abiologics, a Flagship Pioneering startup, has unveiled a groundbreaking approach to developing novel biologic treatments for cancer and immunology. 🧬💊 By leveraging the power of AI, Abiologics is pushing the boundaries of traditional biologics with their innovative Synteins – synthetic proteins based on non-standard amino acids. 🤖🔬 This revolutionary approach has the potential to unlock new possibilities in drug discovery and development. Backed by an impressive $50 million in initial funding, Abiologics has already demonstrated promising results in animal models. 📈🐁 The startup now aims to advance its internal drug pipeline and forge partnerships with key players in the biopharmaceutical industry. CEO and co-founder Avak Kahvejian believes that Synteins could mark the beginning of a new era in biologics, much like the dawn of the antibody era. 🌅💡 This bold vision underscores the transformative potential of Abiologics' technology. As the biotech industry continues to evolve and embrace cutting-edge innovations, startups like Abiologics are at the forefront of driving progress and reshaping the future of medicine. 🚀⚕️ Their AI-driven approach to designing novel biologics could pave the way for more targeted and effective treatments for cancer and immunological disorders. What are your thoughts on the potential impact of Abiologics' Syntein technology on the biotech industry? 💭 Let's engage in a discussion about the future of drug discovery and the role of AI in advancing medical breakthroughs. 🗣️ #Biotech #ArtificialIntelligence #DrugDiscovery #Innovation #FlagshipPioneering

🚀 Exciting News from the Swiss Biotech Sector! 🚀 📈 Record revenues of CHF 7.3 billion 💰 Capital investments surge by over 50% 🔬 Significant licensing and M&A activity, including CRISPR gene editing therapy 💡 Swiss Biotech Report highlights industry resilience and global impact 🌍 Expansion of Global Village platform fosters international collaboration 🏆 Swiss Biotech Success Stories Awards honor trailblazing contributions See the link below to download the report & do not hesitate to reach out with any questions about Biotech investments in Switzerland 🇨🇭 #SwissBiotech #EY #BuildingABetterWorkingWorld

Excited to welcome Stefan N. Lukianov, CEO & Founder of Salve Therapeutics, as a speaker at our event at Alcor Drug Discovery Platform in New Jersey's Crown Plaza! Topic: Revolutionizing Biologics with AI: The Future of Viral Therapies Stefan N. Lukianov, a trailblazer in the field of biotechnology, brings a unique blend of expertise as both the Founder/CEO of Salve Therapeutics, Inc. and an MA student in the Biotechnology Enterprise and Entrepreneurship Program at Johns Hopkins University. His company specializes in pioneering viral-mediated therapies through the innovative application of computational tools. Join us as Stefan shares insights into the transformative potential of AI-mediated computer-aided design in the development of viral biologics. This promises to be an enlightening discussion on the cutting edge of biotechnology innovation. Don't miss out! #ADDP2024 #7thADDP #Alcordrugdiscoveryplatform #LifeSciencesSummits #DrugDiscovery #PreclinicalSummits #USADrugDiscoverySummits  #DrugDiscoverySummits #EuropeanClinicalTrialSummits #Scientist #DrugDiscovery #Preclinical #Medchem #Biology #Protein #Antibodies #Conference #InPersonEvent #Summit #AI #ML #Data #Oncology #DrugDevelopment #Collaboration #Keynote #PanelDiscussion #Oncology #Therapeutics #DrugDesign #SmallMolecules #LargeMolecules #Events #Therapeutics #BigData #Marketing #DigitalMarketing #AIdrug #alcordrug #alcordiscovery #addp2024

This is the moment to re-engineer the entire drug discovery and development process. Driven by growing data sets and new methods, there has been accelerating progress in applications of artificial intelligence to biology, chemistry, and medicine. That’s why Foresite Labs teamed up with ARCH Venture Partners to incubate Xaira Therapeutics, an integrated biotechnology company harnessing this emerging toolkit to deliver innovative medicines to patients faster. Xaira Therapeutics launches with unprecedented capabilities to amass and generate biological, biophysical, and biomedical data, to build and deploy models of increasing scope, and to apply these in a robust product development process. For example, Xaira incorporates AI models and protein design technologies developed in Dr. David Baker’s lab at  Institute for Protein Design, University of Washington, and data generation capabilities in part spun out from Illumina functional genomics and ML R&D efforts. We’re incredibly proud of the team, led by founding CEO Dr. Marc Tessier-Lavigne, and our Board of Directors, including Scott Gottlieb, Alex Gorsky, Carolyn Bertozzi, and others we will announce today. We also thank the interim management team from Foresite Labs who has been involved in this incubation. Backed by ARCH Venture Partners and Foresite Capital, with additional investments from F-Prime Capital, New Enterprise Associates (NEA), Sequoia Capital, Lux Capital, Lightspeed, Menlo Ventures, Two Sigma Ventures, the Parker Institute for Cancer Immunotherapy, SV Angel, among others, Xaira is supported with over $1 billion in committed capital. Learn more on Xaira and our launch from Andrew Dunn and Ryan Cross in Endpoints News: https://lnkd.in/gZ33esk8

Innovating with Intelligence: Unleashing Our AI-Driven Antibody Discovery At iBio, Inc., we're revolutionizing the future of antibody therapeutics through the power of AI. Our proprietary AI-driven technology stack is designed to tackle the most challenging targets in drug development. Here's how we're making it happen: 💡 Patented AI-driven discovery tech stack💡 •Patented epitope-engineering technology • StableHu antibody optimizer coupled with mammalian display • EngageTx next-generation bi-specific antibody platform • ShieldTx antibody masking fully integrated in technology stack 💡Versatile Business Model💡 • Strategic partnerships • Proprietary preclinical pipeline ready for licensing • Exclusive platform licensing for specific disease areas 💡Technology Stack Spurs Rapid Preclinical Pipeline💡 • Pipeline of 6 preclinical programs of hard to drug targets • Targets in focus of major immuno-oncology (I/O) companies with significant deal flow • Promising early CMC development data for lead asset IBIO-101 • Expansion into cardiometabolic through AstralBio partnership Our focus spans major immuno-oncology areas and promising cardiometabolic collaborations, positioning us at the forefront of biotech innovation. #Biotech #Innovation #AntibodyDiscovery #AI #DrugDiscovery #iBio #Partnerships

🌟 AI-Driven Drug Discovery Weekly Roundup 🌟 Welcome back to our weekly series where we share the latest and most exciting developments in the AI-driven drug discovery industry. This week, we highlight groundbreaking advancements from Tempus AI, DeepCure, and UC San Diego: 💡 Tempus AI Files for IPO Tempus AI, a leader in precision medicine data and analytics, has filed for an IPO aiming to raise $100 million. Founded by Groupon co-founder Eric Lefkofsky, Tempus boasts the world’s largest library of clinical and molecular data. Their AI-enabled platform has expanded from genomics to personalized medicine across various fields. With a valuation of $8.1 billion, Tempus is set to revolutionize precision medicine with "Intelligent Diagnostics" that leverage AI to enhance lab test accuracy and personalization. 🧪 DeepCure's Inspired Chemistry Platform, DeepCure has unveiled Inspired Chemistry, an automated synthesis platform that transforms AI-designed small molecule structures into viable drug candidates. This platform was demonstrated by successfully synthesizing the protease inhibitor nirmatrelvir (Paxlovid) and 56 analogs. By automating complex synthesis processes, DeepCure addresses major bottlenecks in drug discovery, facilitating rapid and cost-effective exploration of diverse chemical spaces. Their platform is poised to revolutionize the AI-based drug discovery landscape. 🔬 POLYGON: Accelerating Early Drug Discovery Researchers at UC San Diego have introduced POLYGON, a machine learning algorithm that simulates complex chemistry to expedite early drug discovery. POLYGON focuses on multi-target molecules, potentially reducing side effects compared to traditional therapies. In a recent study, the platform helped synthesize 32 new multi-target cancer drugs, showcasing significant activity against targeted proteins. This open-source tool is a significant step forward in AI-guided precision medicine, paving the way for more efficient drug development. Stay tuned for more updates next week as we continue to explore the latest industry updates and innovations in AI-driven drug discovery! 🚀💊🔬 Join us at the AI Driven Drug Discovery Summit this Novemeber - https://lnkd.in/e-rRQ4Ue #AIDDD #AIDrivenDrugDiscovery #DrugDiscovery #AI #AINews